Table 5 Adverse events with an incidence of 10% or more in the phase Ib safety population, regardless of relationship to study drugs*
N = 31 | ||
|---|---|---|
Any grade | Grade 3 or higher | |
Hyperglycemia | 16(51.6) | 0 |
Diarrhea | 14(45.2) | 3(9.7) |
Rash | 13(41.9) | 1(3.2) |
Aspartate aminotransferase increased | 12(38.7) | 2(6.5) |
Hypercholesterolemia | 11(35.5) | 0 |
Alanine aminotransferase increased | 9(29.0) | 2(6.5) |
Anemia | 9(29.0) | 0 |
Weight decreased | 8(25.8) | 0 |
Nausea | 7(22.6) | 0 |
Blood creatinine increased | 6(19.4) | 0 |
COVID-19 | 6(19.4) | 0 |
Hypophosphatasemia | 6(19.4) | 0 |
Hypertriglyceridemia | 5(16.1) | 1(3.2) |
Hypokalemia | 5(16.1) | 0 |
Proteinuria | 5(16.1) | 0 |
Upper respiratory tract infection | 5(16.1) | 0 |
Urinary tract infection | 5(16.1) | 0 |
Blood cholesterol increased | 4(12.9) | 0 |
Cough | 4(12.9) | 0 |
